Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Terbinafine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR Lamisil AT 1% Gel contains the active ingredient terbinafine which is an antifungal used to treat skin problems caused by fungi in:
2. BEFORE YOU USE LAMISIL AT 1% GEL DO NOT use Lamisil AT 1% Gel if you have:
LAMISIL AT 1% GEL Always use this medicine exactly as described in this leaflet or as advised by your doctor or pharmacist. Adults Lamisil AT 1% Gel is applied once a day, for one week only, for all fungal infections.
25
1% GEL
4. POSSIBLE SIDE EFFECTS Like all medicines, Lamisil AT 1% Gel can cause side effects, although not everybody gets them. STOP using the gel and seek medical help immediately if you have any of the following very rare allergic reactions:
not listed in this leaflet, please tell your doctor. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow
Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
LAMISIL AT 1% GEL Keep out of the sight and reach of children. Do not store above 30°C. Use this medicine within 1 month of opening. Do not use or keep this medicine after the expiry (EXP) date shown on the box and tube. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
6. FURTHER INFORMATION What Lamisil AT 1% Gel contains The active ingredient is terbinafine, 1% w/w. The other ingredients are purified water, ethanol, isopropyl myristate, polysorbate 20, carbomer 974P, sorbitan laurate, benzyl alcohol, sodium hydroxide and butylated hydroxytoluene (see also Section 2 'Important information about some of the ingredients of Lamisil AT 1% Gel'). What Lamisil AT 1% Gel looks like and contents of the pack The gel is available in a 15g aluminium or laminated screw cap tube. Marketing Authorisation Holder Karo Healthcare AB, Box 16184, 103 24 Stockholm, Sweden. Manufacturer Karo Healthcare AB, Klara Norra Kyrkogata 33, 111 22 Stockholm, Sweden. This leaflet was last revised in December 2023.
25
25
5054793 GB / 2003443_1
Lamisil AT 1% Gel comes as gel. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Lamisil AT 1% Gel is terbinafine.
This leaflet reproduces the patient information leaflet approved for Lamisil AT 1% Gel, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
The treatment of tinea pedis (athlete's foot), tinea cruris (dhobie (jock) itch) and tinea corporis (ringworm) caused by Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum) and Epidermophyton floccosum.
Adults
Lamisil AT 1% Gel is applied once daily for all indications.
Duration and frequency of treatment
Tinea corporis, tinea cruris
Tinea pedis (interdigital type)
1 week once a day
1 week once a day
Relief of clinical symptoms usually occurs within a few days. Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified by a physician.
Dosing in special populations
Paediatric populations
Not to be used in children under 16 years of age. Experience with Lamisil AT 1% Gel in children is limited and its use cannot therefore be recommended.
Elderly patients
There is no evidence to suggest that elderly patients require different dosages or experience side effects different from those in younger patients.
Method of Administration
For cutaneous use.
Cleanse and dry the affected areas thoroughly before applying Lamisil AT 1% Gel. The gel should be rubbed in lightly to the affected skin and surrounding area. In the case of intertriginous infection (submammary, interdigital, intergluteal, inguinal) the application may be covered with a light gauze, especially at night.
Known hypersensitivity to terbinafine or any of the excipients contained in the gel (see section 6.1 List of Excipients).
Lamisil AT 1% Gel contains 207.36 mg alcohol (ethanol) in each daily dose which is equivalent to 100 mg/ g of 96% ethanol. Lamisil AT 1% Gel should be used with caution in patients with lesions where alcohol could be irritating, such as lesions which are markedly inflamed or on sensitive areas of the body such as the face.
Lamisil AT 1% Gel is for external use only. It may be irritating to the eyes. In case of accidental contact with the eyes, rinse eyes thoroughly with running water.
Lamisil AT 1% Gel contains butylhydroxytoluene (E321), which may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes.
Lamisil AT 1% Gel contains 10.8 mg benzyl alcohol in each daily dosage which is equivalent to 5 mg/g. Benzyl alcohol may cause mild local irritation.
No drug interactions are known with Lamisil AT 1% Gel, however as a precaution it is recommended that other medicinal products are not applied on the treated areas.
Pregnancy
Animal studies did not reveal any teratogenic or embryofoetotoxic potential of terbinafine.
No cases of malformation in humans have been reported with terbinafine to date. There is limited clinical experience in pregnant women, Lamisil AT 1% Gel should not be used during pregnancy unless clearly indicated.
Lactation
Terbinafine is excreted in breast milk. Therefore, mothers should not use Lamisil AT 1% Gel whilst breastfeeding. Infants must not be allowed to come into contact with any treated skin, including the breast.
Fertility
No effect of terbinafine on fertility have been seen in animal studies (see section 5.3).
Lamisil AT 1% Gel has no influence on the ability to drive and use machines
Local symptoms such as pruritus, skin exfoliation, application site pain, application site irritation, pigmentation disorder, skin burning sensation, erythema, scab may occur at the site of application.
These minor symptoms must be distinguished from hypersensitivity reactions such as widespread pruritus, rash, bullous eruptions and hives, which are reported in sporadical cases but require discontinuation.
In case of accidental contact with the eyes terbinafine hydrochloride may be irritating to the eyes.
In rare cases the underlying fungal infection may be aggravated.
Immune system disorders
Not known: Hypersensitivity
Eye disorders
Rare: Eye irritation
Skin and subcutaneous tissue disorders
Common: Skin exfoliation, pruritus
Uncommon: Skin lesion, scab, skin disorder, pigmentation disorder, erythema, skin burning sensation
Rare: Dry skin, dermatitis contact, eczema
Not known: Rash
General disorders and administration site conditions
Uncommon: Pain, application site pain, application site irritation
Rare: Condition aggravated
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
The low systemic absorption of topical terbinafine renders overdosage extremely unlikely.
Accidental ingestion of one 30 g tube of Lamisil 1% Gel, which contains 300 mg terbinafine base, is comparable to ingestion of one Lamisil 250 mg tablet (adult oral unit dose).
Should a larger amount of Lamisil AT 1% Gel be inadvertently ingested, adverse effects similar to those observed with an overdosage of Lamisil tablets are to be expected. These include headache, nausea, epigastric pain and dizziness.
In case of accidental oral ingestion, the alcohol content has to be considered:
Lamisil AT 1% Gel contains 9.4% w/w alcohol.
Treatment of overdoseIf accidentally ingested, the recommended treatment of overdosage consists of eliminating the active substance, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy if needed.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Lamisil AT 1% Gel. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.